Sundlof feels industry's NDI pain
This article was originally published in The Tan Sheet
FDA's Center for Food Safety and Applied Nutrition currently rejects 80 percent of the new dietary ingredient notifications it receives "because industry doesn't really understand what we require," says center Director Stephen Sundlof. The NDI guidance is "still under review ... but we are pressing to get that out and we know that the industry really wants to have that guidance," Sundlof said at the Food and Drug Law Institute's annual conference April 22 in Washington. Supplement industry stakeholders have long said an NDI guidance would be a key incentive for developing new products, and Sundlof said he realizes publishing the guidance "would be really helpful" to industry. The recent switch by Sens. John McCain, R-Ariz., and Byron Dorgan, D-N.D., from sponsoring a bill that would put new burdens on the industry to backing legislation that requires FDA to complete the NDI notification guidance "as soon as possible" also could compel CFSAN's work (1"The Tan Sheet" March 15, 2010)
You may also be interested in...
Hatch Flips Focus To NDI Guidance In McCain Steroid Bill Negotiations
In a bit of legislative jiu-jitsu, congressional dietary supplement champions have redirected Sen. John McCain from sponsoring a bill that would put new burdens on industry to backing a provision that requires FDA publish a guidance stakeholders have been pushing for
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.
For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion
After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.